预约演示

Kite and Arcellx close multiple myeloma collaboration agreement

2023-02-02

交易

孤儿药细胞疗法快速通道临床2期引进/卖出

Kite, a Gilead Company, and Arcellx have announced the closing of their collaboration agreement to jointly develop and commercialise Arcellx’s late-stage candidate to treat relapsed or refractory multiple myeloma.

Kitehe third most common haeArcellxical malignancy – cancer that begins in blood-forming tissue – in Europe and the US, multiple myelArcellxresents approximately 10% of all relapsed or refractory multiple myelomadeaths caused by such malignancies.

The disease is incurable haematological malignancycoring the need for new treatment options to help improve long-term oumultiple myeloma haematological cancer

Currently in phase 2 clinical development, Arcellx’s CART-ddBCMA is an investigational cell therapy product using patients’ own T-cells that have been genetically altered to target the disease.

The candidate has already been granted FastArcellx OrCART-ddBCMAand Regenerative Medicine Advanced Therapy designations by the US Food and Drug Administration.

“Cell therapy has proven it can change the way cancer is treated by creating a potentially curative therapy for an individual patiFood and Drug Administrationwn t-cells,” Kite’s chief executive officer, Christ Shaw, explained at the time of the original announcement.

“To deliver cell therapy globally, and at scale, it requires a highly coordinated, vertically integrated organisation from R&D to commercialisation to manufacturing, dedicated to the unique needs of this very complex field,” Shaw added.

Announced in December 2022, the terms of the agreement stated Arcellx would receive an upfront cash payment of $225m and $100m equity investment, alongside other potential contingent payments.

The partners will split development, clinical trial and commerArcellxtion costs for CART-ddBCMA and will jointly commercialise the product, each taking 50% of US profits.

Outside the US, Kite will commercialise the product and Arcellx will receive royaltiCART-ddBCMA, with Kite assuming responsibility for the costs involved for any product under the collaboration that is not co-commercialised.

Rami Elghandour,Kiteirman and chief executive officer ofArcellxx, said at the time: “Combining our potKiteally best-in-class CART-ddBCMA therapy for multiple myeloma with Kite’s global leadership in cell therapy provides the foundation for us to commercialise our therapy at scale.

“Most importantly, this collaboration is focused on accelArcellx access for patients in need… We both bring complementary expCART-ddBCMAhe collaboratmultiple myelomah company to contribute to the partnership without duplication or competing interests, which is critical for building long-term value.”

机构